51st week of 2012 patent applcation highlights part 40 |
Patent application number | Title | Published |
20120321595 | TREATMENT OF HEART DISEASE - Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy. | 2012-12-20 |
20120321596 | KIT FOR ADHERING BIOLOGICAL HARD TISSUES - A kit for bonding to biological hard tissues, containing a phosphorylated polysaccharide, a polyvalent metal salt other than phosphates, and a solvent. The adhesive composition for biological hard tissues provided by the kit for bonding to biological hard tissues is suitably used in for medical uses, such as cement for bones or dental cement. In addition, since the adhesive composition has excellent bio-absorbability, it is useful as fusion materials for artificial joint prosthesis, fusion materials for spine fracture, fusion materials for extremity fracture, filling materials for bone tumors in the region of orthopedics, filling materials and restorative materials at dental caries-defective sites, luting materials for prosthetic restorative materials such as inlay and crown, pulp-capping and lining materials, implant surface treatment materials, periodontal disease therapeutic materials, hyperesthesia preventive materials, dental pulp capping materials, substrates for DDS, substrates for systems engineering, and tissue bonding materials in the dental region. | 2012-12-20 |
20120321597 | METHODS AND COMPOSITIONS FOR REGENERATING CONNECTIVE TISSUE - Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament. | 2012-12-20 |
20120321598 | VECTORS AND METHODS FOR LONG-TERM IMMUNE EVASION TO PROLONG TRANPLANT VIABILITY - A method can include making one or more compositions for altering allogeneic cells of a human donor for a human recipient by identifying at least one mismatch in an HLA protein between the human donor and the human recipient; determining a consensus conserved nucleic acid sequence among nucleic acid sequences encoding a domain having the mismatch or among domains having a plurality of mismatches; and forming at least one of the one or more compositions by constructing a virus vector for expressing a sequence targeting the consensus conserved nucleic acid sequence, which when expressed in cells functions as a negative modulator for nucleic acid encoding the domain having the mismatch or the domains having the plurality of mismatches. | 2012-12-20 |
20120321599 | HERPES VIRUS STRAINS - The present invention provides a herpes virus with improved oncolytic properties which comprises a gene encoding an immunomodulatory cytokine and which lacks a functional ICP34.5 gene and a functional ICP47 encoding gene. | 2012-12-20 |
20120321600 | INFANT FORMULA WITH PROBIOTICS AND MILK FAT GLOBULE MEMBRANE COMPONENTS - A nutritional composition is proposed comprising a probiotic and milk fat globule membrane (MFGM) wherein the MFGM and the probiotics mutually potentiate their respective effects and promote complementary beneficial protective mechanisms that reflect physiological synergy. The nutritional composition can be an infant formula, infant cereals, baby food or health care nutritional product. The synergistic effect can include promoting immune maturation and/or immune education and/or reducing inflammation and/or treating or preventing disease or infections. | 2012-12-20 |
20120321601 | Increased In Vivo Circulation Time of Platelets After Storage With A Sialidase Inhibitor - The present invention relates to methods, compositions and kits for increasing the in vivo circulation time of isolated platelets by storing the platelets with one or more sialidase inhibitors. | 2012-12-20 |
20120321602 | OMEGA-3 FATTY ACID NUTRICEUTICAL COMPOSITION AND OPTIMIZATION METHOD - A novel omega-3 fatty acid/lipid based nutraceutical composition and a method of optimizing said omega-3 fatty acid/lipid based nutraceutical composition. The nutraceutical composition and method is based on the insight that different forms of high omega-3 fatty acid lipids (e.g. triglyceride form, ethyl ester form, free fatty acid form, phospholipid form) have different molecular modes and levels of action. Specifically the phospholipid form is likely more effective at promoting membrane fluidity and permeability, while the free fatty acid form is likely more effective at regulating cell receptors, such as the PPARα receptors, that are responsible for various metabolic effects including lipid metabolism. The desirability of producing omega-3 compositions that may act synergistically and thus more robustly to improve health and to some extent mimic markers of life extension such as shown by caloric restriction, along with specific optimization methods, markers, and compositions are taught. | 2012-12-20 |
20120321603 | COMPOSITION AND METHOD FOR STABILIZATION AND DELIVERY OF THERAPEUTIC MOLECULES - A composition and treatment method are disclosed for one or more of alpha, beta, and gamma-Cyclodextrin and a natural molecule or fragment thereof wherein the natural molecule is sometimes Glutathione, is non-acetylated, non-Esterified, and non-fatty acid attached, and the composition is administered parenterally and non-interveneously. | 2012-12-20 |
20120321604 | CARRIER COMPRISING NON-NEUTRALISED TOCOPHERYL PHOSPHATE - The present invention relates to a carrier for the delivery of a nutraceutical or cosmeceutical active comprising non-neutralised tocopheryl phosphate and a hydrophobic vehicle. The present invention also relates to a formulation comprising the carrier and a nutraceutical or cosmeceutical active. | 2012-12-20 |
20120321605 | ARTIFICIAL SALIVA COMPRISING HYALULONIC ACID - Provided is artificial saliva including hyaluronic acid (HA). The artificial saliva may be used to treat xerostomia or oral candidiasis and can be effectively used to prevent or treat complications cased by reduced secretion of saliva, since the artificial saliva is in a physiological range of human saliva and shows adequate antimicrobial activities. | 2012-12-20 |
20120321606 | CRYSTAL STRUCTURES AND METHODS USING SAME - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the identification and uses of said modulators. | 2012-12-20 |
20120321607 | Factor VII Fusion Polypeptides - The present invention relates to a Factor VII (FVII) fusion polypeptide with a prolonged half-life, wherein the FVII polypeptide can be activated or is in the activated form. | 2012-12-20 |
20120321608 | DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 2012-12-20 |
20120321609 | METHOD OF TREATING PSYCHOLOGICAL DISORDERS - A method of desensitizing 5-HT | 2012-12-20 |
20120321610 | METHOD TO INHIBIT NEUROPATHIC PAIN BY INTRATHECAL INJECTION OF PROTEIN PHOSPHATASES - A method and corresponding pharmaceutical composition to inhibit neuropathic pain by injecting intrathecally into a mammalian subject a neuropathic pain-inhibiting amount of a phosphatase falling within E.C. 3.1.3.x, more specifically a protein phosphatase falling within E.C. 3.1.3.16, and most specifically calcineurin. | 2012-12-20 |
20120321611 | Replenishment and Enrichment of Ocular Surface Lubrication - An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents. | 2012-12-20 |
20120321612 | SYSTEMS AND METHODS FOR TREATING POST-OPERATIVE, ACUTE, AND CHRONIC PAIN USING AN INTRA-MUSCULAR CATHETER ADMINISTRATED COMBINATION OF A LOCAL ANESTHETIC AND A NEUROTOXIN PROTEIN - Systems, and methods for the use of such systems, are described that allow for the administration of a combination of a sustained release local anesthetic compound (such as bupivicaine) through a catheter based administration device and direct visualization or percutaneous injection of a neurotoxic protein compound (such as botulinum toxin) for post-operative and refractory treated muscle pain and discomfort in patients having undergone spinal surgery and other muscle splitting or treatments aimed at improving muscle pain. The systems utilize specific catheter-based administration protocols and methods for placement of the catheter in association with muscles surrounding the spine and other anatomical sites within the patient. The utilization of an initial bolus of a specific combination of medications (local anesthetic compound and\or neurotoxic protein compound) followed by a dosage pump administration through the catheter is anticipated. A variety of local anesthetics (in addition to bupivicaine) and a number of different neurotoxin proteins (in addition to the Botulinum toxin) may be utilized in the medicament administration protocols described. | 2012-12-20 |
20120321613 | MOLECULAR TARGETS FOR HEALING OR TREATING WOUNDS - The invention relates to at least one molecular target for healing or treating wounds and, in particular chronic, human wounds. The molecular target is nWASP or a protein 50% homolgous therewith and which retains the same activity as nWASP protein, such as WASP. Further, the invention concerns a novel therapeutic for treating said wounds and a novel gene therapy approach, involving said molecular target, for treating said wounds. | 2012-12-20 |
20120321614 | ANTIBODIES TO C-MET - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention. | 2012-12-20 |
20120321615 | Assay for Metastatic Colorectal Cancer - Disclosed herein is a method for predicting the prognosis, the likelihood of metastasis in, or the desirability of administering an aggressive therapy to, a subject with colorectal cancer, comprising determining, in a sample from the subject, the level of phosphorylation of one or more of certain proteins compared to a positive and/or negative reference standard; or the total amount of COX-2 protein compared to a positive and/or negative reference standard. Also described are methods for treating subjects likely to develop metastatic colorectal carcinoma, and pharmaceutical compositions and kits for implementing the methods of the invention. | 2012-12-20 |
20120321616 | STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS - The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention. | 2012-12-20 |
20120321617 | HUMANIZED ANTI-IL 10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the 1L-10 receptor α (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL-10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof. | 2012-12-20 |
20120321618 | HUMANIZED ANTI-IL 10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof. | 2012-12-20 |
20120321619 | ANTI-C4.4A ANTIBODIES AND USES THEREOF - The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa C4.4a polypeptide, which is over expressed in several tumors, e.g. lung, colorectal, pancreas, prostate, renal and breast cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 2012-12-20 |
20120321620 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 2012-12-20 |
20120321621 | INHIBITION OF FcyR-MEDIATED PHAGOCYTOSIS WITH REDUCED IMMUNOGLOBULIN PREPARATIONS - The invention relates to pharmaceutical compositions for inhibiting FcγR-mediated phagocytosis that include a reduced immunoglobulin inhibitor of FcγR-mediated phagocytosis, such as anti-D, in combination with a pharmaceutically acceptable carrier. The invention also relates to methods for treating or preventing an autoimmune or alloimmune disease that include administering to a subject in need thereof a therapeutically effective amount of a reduced immunoglobulin inhibitor of FcγR-mediated phagocytosis. | 2012-12-20 |
20120321622 | Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases - The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of CSCPK and related kinases; to methods of inhibiting cancer stem cells by using a kinase inhibitor; to pharmaceutical compositions containing such compounds; and to methods of using such compounds in the treatment of a protein kinase related disorder in a mammal; and to processes of making such compounds and intermediates thereof. | 2012-12-20 |
20120321623 | ILT3 Polypeptides and Uses Thereof - This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention. | 2012-12-20 |
20120321624 | TARGETING THE NEUROMUSCULAR JUNCTION FOR TREATMENT - Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular junction. Compositions include a neuromuscular junction targeting peptide coupled to a therapeutic agent. Compositions may further include a linker peptide. Methods for targeting therapeutic agents to neuromuscular junctions and treating diseases and conditions affecting the neuromuscular junction include administering a composition including a neuromuscular junction targeting peptide coupled to a therapeutic agent. | 2012-12-20 |
20120321625 | ANTIBODIES TO OX-2/CD200 AND USES THEREOF IN INHIBITING IMMUNE RESPONSES - This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival. | 2012-12-20 |
20120321626 | MULTI-SPECIFIC FAB FUSION PROTEINS AND METHODS OF USE - The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner. | 2012-12-20 |
20120321627 | BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2012-12-20 |
20120321628 | HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF - Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided. | 2012-12-20 |
20120321629 | STEM CELL FACTOR INHIBITOR - Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases. | 2012-12-20 |
20120321630 | ANTIBODIES AGAINST G-CSFR AND USES THEREOF - The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor. | 2012-12-20 |
20120321631 | ANTI-INFLAMMATORY AGENTS - This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions. | 2012-12-20 |
20120321632 | NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE - The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The composition of the invention blocks prolactin receptor-mediated signaling. | 2012-12-20 |
20120321633 | ANTI-HUMAN EPO RECEPTOR ANTIBODIES AND METHODS OF USE - Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD. | 2012-12-20 |
20120321634 | ESTROGEN RECEPTORS AND METHODS OF USE - The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies. | 2012-12-20 |
20120321635 | Composition Containing Inhibitors of the Expression or Activity of SH3RF2 for Preventing or Treating Cancer - The present invention relates to a composition comprising an inhibitor of the expression or activity of SH3 domain containing ring finger 2 (SH3RF2) for preventing or treating cancers. More specifically, since the SH3RF2 protein, of which the expression level increases in various cancer tissues, binds to PAK4, which is a cancer-associated gene, to regulate an apoptosis inhibitory function of the PAK4 protein by ubiquitination activity of SH3RF2 RING domain, cancer cells, in which the expression of SH3RF2 is inhibited, sensitively respond to the induction of apoptosis to promote apoptosis and reduce in vivo tumorigenicity, such that the inhibitor of the expression or activity of SHRF2 can be useful as a composition for preventing or treating cancers. | 2012-12-20 |
20120321636 | ANTIBODIES SPECIFIC FOR SCLEROSTIN AND METHODS FOR INCREASING BONE MINERALIZATION - Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures. | 2012-12-20 |
20120321637 | COMBINATION CANCER THERAPY WITH HERV INHIBITION - Embodiments are directed to compositions and methods related combination therapy with HERV inhibition. | 2012-12-20 |
20120321638 | FORMULATION COMPRISING AN ANTIBODY AGAINST P-SELECTIN - This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation. | 2012-12-20 |
20120321639 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF STAT5 IN PROSTATE CANCER CELLS - The present invention relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells. | 2012-12-20 |
20120321640 | VON WILLEBRAND FACTOR SPECIFIC BINDING AGENTS AND USES THEREOF - The invention provides new uses, compositions and methods of administration for specific binding agents to von Wiliebrand Factor (vWF) in patients with thromboembolic disorders and in particular new combined uses with thrombolytic agents such as tissue plasminogen activator in patients with thromboembolic disorders such as e.g. ischemic stroke. Furthermore, a new group of vWF binding agents and an improved Middle Cerebral Artery Thrombosis Model in guinea pigs to study the effects of stroke such as ischemia (oxygen and glucose depriviation) and hemorrhage (bleeding), in particular hemorrhage, are provided. | 2012-12-20 |
20120321641 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER - According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody comprising a heavy chain variable region that comprises SEQ ID NOS: 39, 40, and 41 and a light chain variable region that comprises SEQ ID NOS: 43, 44, and 45 or a fragment thereof as an active ingredient and having immunological reactivity with a CAPRIN-1 protein. | 2012-12-20 |
20120321642 | Methods of Treating Gout using IL-1beta Antagonists - This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans. | 2012-12-20 |
20120321643 | ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND USES THEREOF - The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×10 | 2012-12-20 |
20120321644 | METHODS FOR DIAGNOSING MOOD DISORDERS - The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Aβ protein, including Aβ | 2012-12-20 |
20120321645 | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins - Compositions and methods utilizing immunomodulating agents can either stimulate or indirectly augment the immune system or have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used to treat disease caused by asthma and chronic inflammation such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation. | 2012-12-20 |
20120321646 | Methods for Enhancing Anti-Tumor Antibody Therapy - Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule. | 2012-12-20 |
20120321647 | STRUCTURED RNA MOTIFS AND COMPOUNDS AND METHODS FOR THEIR USE - Disclosed are compositions and methods involing riboswitches and RNA motifs. For example, disclosed are compositions and methods involving glutamine-responsive riboswitches, S-adenosylmethionine-repsonsive riboswitches, S-adenosylhomocysteine-repsonsive riboswitches, glutamine riboswitches, SAM/SAH riboswitches, glnA riboswitches, Downstream-peptide riboswitches, crcB riboswitches, pfl riboswitches, yjdF riboswitches, manA riboswitches, wcaG riboswitches, epsC riboswitches, ykkC-III riboswitches, psaA riboswitches, psbA riboswitches, PhotoRC-I riboswitches, PhotoRC-II riboswitches, and psbNH riboswitches. | 2012-12-20 |
20120321648 | USE OF ISLET GLUCOSE-6-PHOSPHATASE RELATED PROTEIN AS A DIAGNOSTIC TOOL AND THERAPEUTIC TARGET FOR AUTOIMMUNE DIABETES - A method and compositions for detecting autoimmunity to islet glucose-6-phosphatase related protein (IGRP). Detection of IGRP autoantibodies alone, and in combination with other molecules such as the 65-kDa form of glutamate decarboxylase (GAD | 2012-12-20 |
20120321649 | Peptide Vaccines for Cancers Expressing Tumor-Associated Antigens - The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines. | 2012-12-20 |
20120321650 | COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS - Epitopes derived from a protein present in an atherosclerotic plaque, such as apolipoprotein B-100, are presented. The epitopes can be used in a method of treating atherosclerosis by continuous subcutaneous or transcutaneous administration of a therapeutically effective amount of the epitope to a subject. Administering the epitope to the subject can induce a specific regulatory immune response, such as a Treg response. A composition or patch containing the epitope and adapted for the prophylactic or therapeutic treatment of a subject are also presented. | 2012-12-20 |
20120321651 | Anti-IGE Vaccines - The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs. | 2012-12-20 |
20120321652 | PEPTIDES FOR ACTIVE ANTI-CYTOKINE IMMUNIZATION - Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient. | 2012-12-20 |
20120321653 | NOVEL CHIMERIC POLYNUCLEOTIDES AND POLYPEPTIDES ENABLING THE SECRETION OF A POLYPEPTIDE OF INTEREST IN COMBINATION WITH EXOSOMES AND USES THEREOF - The present invention provides a chimeric polypeptide comprising a plurality of polypeptide domains that are capable of being secreted in combination with membrane vesicles and in particular exosomes. | 2012-12-20 |
20120321654 | INFECTIOUS CLONES OF TORQUE TENO VIRUS - The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen. | 2012-12-20 |
20120321655 | LENTIVIRUS VACCINE BASED ON THE RECOMBINANT VIRAL VACCINE AGAINST YELLOW FEVER - The present invention relates to an attenuated, recombinant viral vaccine against yellow fever which expresses heterologous sequences of a lentivirus and is used as an immunisation agent to induce an immune response to lentivirus. | 2012-12-20 |
20120321656 | OLIGOPEPTIDES AND THEIR USE FOR TREATING INFECTIOUS DISEASES - The invention discloses identification, method of making and therapeutic use of synthetic oligopeptides for the treatment of infectious diseases, in particular tuberculosis. The oligopeptides are designed using virulence mediating protein for | 2012-12-20 |
20120321657 | GROUP A STREPTOCOCCUS MULTIVALENT VACCINE - Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A | 2012-12-20 |
20120321658 | IMMUNOGENIC COMPOSITION COMPRISING S. PNEUMONIAE POLYSACCHARIDES CONJUGATED TO CARRIER PROTEINS - The present invention relates to an immunogenic composition comprising at least 2 different | 2012-12-20 |
20120321659 | HBV CORE ANTIGEN PARTICLES WITH MULTIPLE IMMUNOGENIC COMPONENTS ATTACHED VIA PEPTIDE LIGANDS - This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them. | 2012-12-20 |
20120321660 | CONJUGATION PROCESS OF BACTERIAL POLYSACCHARIDES TO CARRIER PROTEINS - Process for conjugation of bacterial saccharides including | 2012-12-20 |
20120321661 | Recombinant Measles Virus Useful as a Bivalent Vaccine Against Measles and Malarial Infections - Provided herein is a vaccine which is safe and effective against malarial infection and a vector which is used in the manufacture of this vaccine and to provide a bivalent vaccine which exhibits an excellent preventive effect against measles virus and malarial infection and which eliminates complexity at the time of inoculation. Also provided is a recombinant measles virus in which is inserted a gene which encodes a protein involved in preventing malarial infection in the measles virus genome. The present invention also provides a bivalent vaccine against measles and malarial infection which contains the recombinant measles virus. It also provides a method of manufacturing a vaccine against malarial infection which is characterized by using a measles virus as a vaccine vector in the manufacture of a vaccine against malarial infection | 2012-12-20 |
20120321662 | Methods of Eliciting or Boosting a Cellular Immune Response - Site-specific | 2012-12-20 |
20120321663 | LIVE VACCINE FOR AVIAN DISEASES - A method for preparing a vaccine composition to be implemented in a locally administered treatment for avian viral disease, includes at least the step of: a) extemporaneously mixing a vaccine, including at least one live virus selected from a virus belonging to one or more strains of the avian disease, with an adjuvant diluent (DA), characterized in that the adjuvant diluent is a continuous aqueous phase oil-in-water emulsion or oil-in-water microemulsion. | 2012-12-20 |
20120321664 | MODULATION OF YEAST-BASED IMMUNOTHERAPY PRODUCTS AND RESPONSES - Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions. | 2012-12-20 |
20120321665 | COMPOSITIONS AND METHODS FOR TREATING AIRWAY INFLAMMATORY DISEASES - A composition for treating an airway inflammatory disease having high molecular weight, crosslinked hyaluronan and at least one aeroallergen is provided. A method of inducing immune tolerance to one or more aeroallergens in a mammalian subject suffering from or at risk of developing an airway inflammatory disease, and a method of treating a human subject suffering from or at risk of developing an airway inflammatory disease or condition of the lungs are also provided. | 2012-12-20 |
20120321666 | T CELL THERAPY FOR B CELL LYMPHOMA - Disclosed are methods and compositions for improving anti-tumor response and survivability in patients with cancer, such as non-Hodgkin lymphoma. In certain aspects, methods are provided for infusing lymphoma patients with T cells that are propagated ex vivo. Also provided are methods and compositions for propagating canine T cells ex vivo for infusion into cancer patients. | 2012-12-20 |
20120321667 | T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS - The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same. | 2012-12-20 |
20120321668 | PEPTIDES DERIVED FROM HIV-1 gp41 TRANSMEMBRANE - The present invention relates to peptides, derivatives and analogs comprising an amino acid sequence derived from the transmembrane domain of HIV gp41 protein, pharmaceutical compositions comprising same, and uses thereof for therapy of inflammatory diseases and disorders, such as T-cell and/or monocyte mediated diseases. | 2012-12-20 |
20120321669 | ANTIGENIC COMPOSITIONS - The invention relates to antigenic compositions and to methods for immunizing animals using same. The antigenic compositions comprise a lipid formulation most usually in solid form, and at least one antigenic component. A preferred antigenic component is a living organism. In a preferred embodiment the composition is formulated for oral administration. | 2012-12-20 |
20120321670 | FORMULATIONS OF NANO-CARRIERS AND METHODS OF PREPARING THE SAME - A method of preparing nano-carriers is disclosed. The method includes mixing an organic solution of a drug and an organic solution of a biological agent separately with a predetermined amount of water having one or more dissolved surfactants to obtain a first mixture and a second mixture respectively. Subsequently, the first mixture and the second mixture are homogenized separately to obtain a solution of nano-crystals of the drug and a solution of nano-particles of the biological agent respectively. Thereafter, the solution of nano-crystals of the drug and the solution of nano-particles of the biological agent are together subjected to an ultra-sound homogenization to obtain a solution of nano-carriers. An interfacial extraction and/or a dialysis are then performed on the solution of nano-carriers to obtain the nano-carriers. Formulations of the nano-carriers are also disclosed. | 2012-12-20 |
20120321671 | Method for reducing heat loss in neonatal mammalian subjects by transplanting brown adipocytes or precursors thereof - A method for modulating heat loss in a neonatal mammalian subject is disclosed herein that includes providing exogenous brown adipocytes, or precursors thereof, to an internal site in the neonatal mammalian subject. | 2012-12-20 |
20120321672 | Method of treating attention deficit hyperactivity disorder - The present invention relates to a method of treating attention deficit hyperactivity disorder (ADHD) and attention deficit disorder (ADD) by administration of activated-potentiate form of antibodies to brain-specific protein S-100 and activated-potentiate form of antibodies to endothelial NO synthase. | 2012-12-20 |
20120321673 | TRANSDERMAL DRUG DELIVERY SYSTEM AND METHOD OF USING THE SAME - A transdermal drug delivery system comprising a steroid as an active agent, wherein the steroid may be clobetasol propionate, betamethasone dipropionate, amcinonide, or loteprednol etabonate. The transdermal drug delivery system also comprises a pressure-sensitive adhesive layer and a support, wherein the steroid is present in the pressure-sensitive adhesive layer, and wherein the pressure-sensitive adhesive layer is provided on a support. The transdermal drug delivery system may be applied onto the eyelid of a patient in need thereof, in order to treat a disease of the eyelid, such as chalazion, blepharitis or meibomian gland dysfunction. | 2012-12-20 |
20120321674 | Technology for Preventing Abuse of Solid Dosage Forms - Abuse resistant pharmaceutical formulations are provided that contain one or more abusable drugs and one or more abuse deterrent components. The abuse deterrent component(s) prevent the abusable drug(s) from being removed/extracted to an appreciable extent and/or rate. The abuse deterrent component(s) may be in the form of pellets, beads, beadlets, granules, powders, or the like, and may comprise a core that contains a material that is both hydrophilic and hydrophobic, and optionally a pH-dependent coating. | 2012-12-20 |
20120321675 | METHODS OF INHIBITING CATARACTS AND PRESBYOPIA - Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a β | 2012-12-20 |
20120321676 | EXOSOMES DERIVED FROM RETICULOCYTES INFECTED WITH PLASMODIUM SP., METHOD FOR OBTAINING THEM AND USES THEREOF - The present invention belongs to the field of vaccines for the prevention and prophylaxis against malaria, more specifically it relates to exosomes isolated from reticulocytes infected with | 2012-12-20 |
20120321677 | COATED SOLID PREPARATION - A montelukast-containing coated solid preparation can be applied to one-dose package, wherein the humidity stability of montelukast or a pharmacologically acceptable salt thereof contained therein is maintained even when the preparation is unpacked. A coated solid preparation contains as an active ingredient montelukast or a pharmacologically acceptable salt thereof and is coated with a coating layer comprising polyvinyl alcohol and swelling clay, wherein the mass ratio of the above-described polyvinyl alcohol to the above-described swelling clay in the above-described coating layer is 8:2 to 3:7. | 2012-12-20 |
20120321678 | INTRA-ARTICULARLY SUPPLEMENTATION METHOD FOR TREATING JOINT DISEASES AND INJURIES - A method of producing a hydrogel for intra-articular supplement comprising the steps of:
| 2012-12-20 |
20120321679 | Method Of Producing A Silicone Oil Composition - To provide a method that efficiently produces a silicone oil composition in which cross-linked silicone particles uniformly dispersed in amino-modified silicone oil. This invention is a method of producing a silicone oil composition, characterized by removing water after mixing an aqueous suspension of cross-linked silicone particles having an average particle diameter in the range of 0.1 to 500 μm with an aqueous emulsion of an amino-modified silicone oil having an average emulsion particle diameter in the range of 0.05 to 100 μm. | 2012-12-20 |
20120321680 | LIQUID CLEANING AND/OR CLEANSING COMPOSITION - The present invention relates to a liquid, cleaning and/or cleansing composition comprising biodegradable abrasive cleaning particles. | 2012-12-20 |
20120321681 | LIQUID CLEANING AND/OR CLEANSING COMPOSITION - The present invention relates to a liquid, cleaning and/or cleansing composition comprising biodegradable abrasive cleaning particles. | 2012-12-20 |
20120321682 | COSMETIC COMPOSITIONS COMPRISING MESOPOROUS TITANIA AND METHODS OF USE - The disclosure relates to a cosmetic composition comprising mesoporous titania with a particle size optimized to provide UV light absorption without the risk of penetrating the skin; and to methods for preventing or reducing ultraviolet radiation damage to the body. The particle size of the mesoporous titania is typically from about 0.3 microns to about 250 microns. The pore size of the mesoporous titania is typically from about 2 nm to about 100 nm. The crystallite/wall size of the mesoporous titania is typically from about 2 nm to about 200 nm. | 2012-12-20 |
20120321683 | Liposome-Encapsulated Bicelles and Use Thereof in Diluted Systems - The aim of the invention is to preserve the morphology of bicelles in high-water-content environments. For this purpose, the invention relates to a liposome comprising, in its internal aqueous medium, at least one bicelle. The bicelles concentration in said aqueous means is between 5 and 25% dry weight in relation to the end liposome. The invention also relates to the use of said liposomes for the encapsulation of active principles, as well as to the use thereof as a medicament or to produce a cosmetic product. The invention further relates to the method for obtaining said liposomes. | 2012-12-20 |
20120321684 | Color Cosmetic - A foundation having a shade which covers a wide spectrum of different skin tones and undertones, comprises red and gold interference pigments, which provide a formula that is adaptable to both red and yellow skin undertones. The composition virtually eliminates the risk of application of the wrong foundation color, and provides enhanced color and textural effects, and superior optical performance. | 2012-12-20 |
20120321685 | COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER - The invention relates to pharmaceutical or cosmetic compositions preferably in the form of microcapsules or microparticles which include at least one active ingredient and an oil or a mixture of oils wherein the oil or mixture of oils alone or in combination with the active ingredient have a specific gravity higher than the specific gravity of water. The invention further relates to a process for preparing said compositions. | 2012-12-20 |
20120321686 | Antifungal Material - The present invention relates to antifungal materials, particularly to nanoparticles comprising or consisting of a non-persistent inorganic support material such as Tricalciumphosphate (TCP) and copper as a dopant in the form of Cu | 2012-12-20 |
20120321687 | COMPOSITIONS AND METHODS FOR USING AND IDENTIFYING ANTIMICROBIAL AGENTS - The present invention provides proteins with antimicrobial activity, and methods for treating subjects by administering the proteins. In particular, the invention provides methods for treating and/or preventing microbial diseases and infections. The present invention further provides the target for these antimicrobial agents, as well as assays for identifying regulators of the target. | 2012-12-20 |
20120321688 | USE OF GLEDITSIA SAPONINS FOR CONTROLLING MOLLUSC PESTS - Method of using saponins from at least one plant of the | 2012-12-20 |
20120321689 | ANTIBACTERIAL RESIN COMPOSITION DERIVED FROM A MASTERBATCH, ANTIBACTERIAL FIBER, ANTIBACTERIAL FILM AND METHOD FOR MANUFACTURING THE ANTIBACTERIAL RESIN COMPOSITION DERIVED FROM A MASTER BATCH - The present invention relates to an antibacterial resin composition derived from a master batch, an antibacterial fiber, an antibacterial film, and a producing method of an antibacterial resin composition therefrom, comprising a polyethylene terephthalate resin as the component (A), and a polybutylene terephthalate resin as the component (B), an antibacterial glass which elutes silver ions as a component (C), which is characterized by having a composition formulated below.
| 2012-12-20 |
20120321690 | ADHESIVE PATCH - The present invention provides a patch having a backing and a pressure-sensitive adhesive layer on the backing, wherein the pressure-sensitive adhesive layer contains a pressure-sensitive adhesive base composed of a polymer having a hydroxyl group, a drug, polyvinylpyrrolidone and a multivalent metal chloride. | 2012-12-20 |
20120321691 | CLAY-BASED HEMOSTATIC AGENTS AND DEVICES FOR THE DELIVERY THEREOF - A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate. Another device is a bandage comprising a substrate, a mesh mounted on the substrate, and particles of a clay material retained in the mesh. A hemostatic sponge comprises a substrate, a hemostatic material disposed on a first surface of the substrate, and a release agent disposed on a second surface of the substrate. The release agent is disposed on the wound-contacting surface of the substrate. When treating a bleeding wound, application of the hemostatic sponge causes at least a portion of the hemostatic material to come into contact with blood through the release agent and through the substrate. | 2012-12-20 |
20120321692 | Methods and Dressings for Sealing Internal Injuries - Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings. | 2012-12-20 |
20120321693 | PRG4 TREATMENT FOR INTERSTITIAL CYSTITIS - The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients via administration of a therapeutically effective concentration of PRG4. | 2012-12-20 |
20120321694 | COMPOSITIONS AND USES - Compositions and methods comprising or using a combination of an adjuvant such as AS01B and an antigen such as a β-amyloid antigen are provided. The compositions and methods provided are particularly useful for prevention or treatment of Alzheimer's disease. Suitable β-amyloid antigens are Aβ1-5, Aβ1-6, Aβ1-7, Aβ1-10, Aβ1-14, Aβ1-15, Aβ2-7, Aβ2-8, Aβ3-7, Aβ3-8, Aβ11-16, Aβ11-17, Aβp(E)3-7, Aβp(E)3-8, Aβp(E)3-40, Aβp(E)3-42, Aβp(E)11-16, Aβp(E)11-17, Aβp(E)11-40 or Aβp(E)11-42, optionally with a protein carrier. Suitable adjuvants comprise QS21, 3D-MPL or an AGP, optionally in combination with a liposome. | 2012-12-20 |